Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention
暂无分享,去创建一个
N. Wareham | W. Koenig | K. Khaw | S. Boekholdt | A. Catapano | E. Levin | A. Groen | E. Stroes | P. Knaapen | N. Nurmohamed | R. Hoogeveen | M. Bom | A. Baragetti | J. Pereira | V. Zampoleri | Renate M. Hoogeveen | N. Wareham | E. Stroes | Albert K. Groen | A. L. Catapano | A. Catapano
[1] Stephen A. Williams,et al. Plasma protein patterns as comprehensive indicators of health , 2019, Nature Medicine.
[2] T. Vilsbøll,et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2019, The New England journal of medicine.
[3] A. Catapano,et al. Multilevel Models to Estimate Carotid Intima-Media Thickness Curves for Individual Cardiovascular Risk Evaluation. , 2019, Stroke.
[4] B. Zinman,et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.
[5] Jeffrey Dean,et al. Machine Learning in Medicine , 2019, The New England journal of medicine.
[6] Declare–Timi Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .
[7] Deepak L. Bhatt,et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.
[8] Charles A. Taylor,et al. Predictive value of targeted proteomics for coronary plaque morphology in patients with suspected coronary artery disease , 2018, EBioMedicine.
[9] Odyssey Outcomes Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018 .
[10] A. Konradi,et al. Epidemiology of cardiovascular risk factors in two population-based studies. , 2018, Atherosclerosis. Supplements.
[11] Chyke A Doubeni,et al. Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.
[12] Daniel Levy,et al. Protein Biomarkers of Cardiovascular Disease and Mortality in the Community , 2018, Journal of the American Heart Association.
[13] Kipp W. Johnson,et al. Artificial Intelligence in Cardiology. , 2018, Journal of the American College of Cardiology.
[14] E. Ingelsson,et al. Multiplex proteomics for prediction of major cardiovascular events in type 2 diabetes , 2018, Diabetologia.
[15] E. Ingelsson,et al. Circulating proteins as predictors of incident heart failure in the elderly , 2018, European journal of heart failure.
[16] M. Netea,et al. Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases , 2017, European heart journal.
[17] M. Budoff,et al. Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA. , 2017, JACC. Cardiovascular imaging.
[18] H. Rashid,et al. Computed Tomographic Coronary Angiography–Derived Plaque Characteristics Predict Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis , 2018, Circulation. Cardiovascular imaging.
[19] V. Fuster,et al. Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. , 2017, Journal of the American College of Cardiology.
[20] J. Leipsic,et al. Comparison of Coronary CT Angiography, SPECT, PET, and Hybrid Imaging for Diagnosis of Ischemic Heart Disease Determined by Fractional Flow Reserve , 2017, JAMA cardiology.
[21] P. Libby,et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.
[22] Deepak L. Bhatt,et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease , 2017, The New England journal of medicine.
[23] A. Keech,et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.
[24] Lawrence A Leiter,et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.
[25] Mark R Segal,et al. Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease. , 2016, JAMA.
[26] John B Buse,et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.
[27] Gediminas Adomavicius,et al. Adapting machine learning techniques to censored time-to-event health record data: A general-purpose approach using inverse probability of censoring weighting , 2016, J. Biomed. Informatics.
[28] Tianqi Chen,et al. XGBoost: A Scalable Tree Boosting System , 2016, KDD.
[29] A. Hoes,et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.
[30] L. Lind,et al. Discovery of New Risk Markers for Ischemic Stroke Using a Novel Targeted Proteomics Chip , 2015, Stroke.
[31] K. Borgwardt,et al. Machine Learning in Medicine , 2015, Mach. Learn. under Resour. Constraints Vol. 3.
[32] Yu-Fang Jin,et al. Transformative Impact of Proteomics on Cardiovascular Health and Disease: A Scientific Statement From the American Heart Association , 2015, Circulation.
[33] D. Rader,et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study , 2015, The lancet. Diabetes & endocrinology.
[34] Martin McKee,et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. , 2014, The New England journal of medicine.
[35] Jennifer G. Robinson,et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.
[36] M. Bots,et al. Time-Dependent Changes in Atherosclerotic Plaque Composition in Patients Undergoing Carotid Surgery , 2014, Circulation.
[37] J. Stenvang,et al. Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability , 2014, PloS one.
[38] S. Butz,et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice , 2011, Nature Medicine.
[39] Ewout W Steyerberg,et al. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.
[40] Miodrag Lovric,et al. International Encyclopedia of Statistical Science , 2011 .
[41] Tso-Jung Yen,et al. Discussion on "Stability Selection" by Meinshausen and Buhlmann , 2010 .
[42] N. Meinshausen,et al. Stability selection , 2008, 0809.2932.
[43] G. Boysen,et al. European Guidelines on Cardiovascular Disease Prevention , 2009, International journal of stroke : official journal of the International Stroke Society.
[44] D. Levy,et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. , 2006, The New England journal of medicine.
[45] A. Hoes,et al. [Guidelines on cardiovascular disease prevention in clinical practice]. , 2005, Revue medicale de Liege.
[46] R. Peters,et al. Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The Prospective EPIC (European Prospective Investigation into Cancer and nutrition)–Norfolk Population Study , 2004, Circulation.
[47] Rich Caruana,et al. Ensemble selection from libraries of models , 2004, ICML.
[48] N. Day,et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. , 1999, British journal of cancer.
[49] David H. Wolpert,et al. Stacked generalization , 1992, Neural Networks.
[50] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.